From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5)

被引：34

作者：

Leong, Darryl P. ^{[1
,2
]}

McMurray, John J., V ^{[3
]}

Joseph, Philip G. ^{[1
,2
]}

Yusuf, Salim ^{[1
,2
]}

机构：

[1] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada

[2] McMaster Univ, Hamilton, ON, Canada

[3] Univ Glasgow, British Heart Fdn Cardiovasc Res Ctr, Glasgow, Lanark, Scotland

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2019年 / 74卷 / 05期

关键词：

ACE-I; ARB; ARNI; coronary disease; heart failure; CONVERTING-ENZYME-INHIBITORS; LEFT-VENTRICULAR DYSFUNCTION; RENIN-ANGIOTENSIN SYSTEM; ACUTE MYOCARDIAL-INFARCTION; 2013 ACCF/AHA GUIDELINE; ASSOCIATION TASK-FORCE; EJECTION FRACTION; CARDIOVASCULAR EVENTS; RANDOMIZED-TRIAL; HIGH-RISK;

D O I：

10.1016/j.jacc.2019.04.068

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The pharmacological inhibition of the renin-angiotensin-aldosterone system as a therapeutic strategy is one of the most significant advances in the treatment and prevention of cardiovascular disease in heart failure with reduced ejection fraction and in coronary artery disease. Recently, the addition of neprilysin inhibition to angiotensin receptor blockade has been shown to be even more effective than angiotensin-converting enzyme inhibition alone in heart failure with reduced ejection fraction, marking an important new milestone in heart failure treatment. This review summarizes the major trials that have informed the clinical role of inhibition of the renin-angiotensin-aldosterone and neprilysin pathways, as well as the limitations of these strategies. (C) 2019 by the American College of Cardiology Foundation.

引用

页码：683 / 698

页数：16

共 73 条

[11]

COLLINS R, 1995, LANCET, V345, P669

[12] Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials [J].

Dagenais, Gilles R. ;

Pogue, Janice ;

Fox, Kim ;

Simoons, Marteen L. ;

Yusuf, Salim .

LANCET, 2006, 368 (9535) :581-588

[13]

DEBOLD AJ, 1979, P SOC EXP BIOL MED, V161, P508

[14]

DEVITA C, 1994, LANCET, V343, P1115

[15] Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction:: a systematic overview of data from individual patients [J].

Flather, MD ;

Yusuf, S ;

Kober, L ;

Pfeffer, M ;

Hall, A ;

Murray, G ;

Torp-Pedersen, C ;

Ball, S ;

Pogue, J ;

Moyé, L ;

Braunwald, E .

LANCET, 2000, 355 (9215) :1575-1581

[16]

Fox KM, 2003, LANCET, V362, P782

[17] Indications for ACE inhibitors in the early treatment of acute myocardial infarction -: Systematic overview of individual data from 100,000 patients in randomized trials [J].

Franzosi, MG ;

Santoro, E ;

Zuanetti, G ;

Baigent, C ;

Collins, R ;

Flather, M ;

Kjekshus, J ;

Latini, R ;

Liu, LS ;

Maggioni, AP ;

Sleight, P ;

Swedberg, K ;

Tognoni, G ;

Yusuf, S ;

Tavazzi, L ;

Ball, S ;

Kober, L ;

Torp-Pedersen, C ;

Braunwald, E ;

Moyé, L ;

Pfeffer, M ;

Santoro, L ;

Pogue, J ;

Wang, Y .

CIRCULATION, 1998, 97 (22) :2202-2212

[18] Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure [J].

Fu, Shihui ;

Ping, Ping ;

Wang, Fengqi ;

Luo, Leiming .

JOURNAL OF BIOLOGICAL ENGINEERING, 2018, 12

[19]

GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450

[20] Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction [J].

Gaziano, Thomas A. ;

Fonarow, Gregg C. ;

Claggett, Brian ;

Chan, Wing W. ;

Deschaseaux-Voinet, Celine ;

Turner, Stuart J. ;

Rouleau, Jean L. ;

Zile, Michael R. ;

McMurray, John J. V. ;

Solomon, Scott D. .

JAMA CARDIOLOGY, 2016, 1 (06) :666-672

← 1 2 3 4 5 6 7 8 →